These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 38914663

  • 1. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.
    Ma MJ, Shi YH, Liu ZD, Zhu YQ, Zhao GY, Ye JY, Li FX, Huang XT, Wang XY, Wang JQ, Xu QC, Yin XY.
    Oncogene; 2024 Jul; 43(31):2405-2420. PubMed ID: 38914663
    [Abstract] [Full Text] [Related]

  • 2. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
    Liu ZD, Shi YH, Xu QC, Zhao GY, Zhu YQ, Li FX, Ma MJ, Ye JY, Huang XT, Wang XY, Xu X, Wang JQ, Zhao W, Yin XY.
    Cancer Lett; 2024 Mar 31; 585():216640. PubMed ID: 38290659
    [Abstract] [Full Text] [Related]

  • 3. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 4. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts.
    Konaté MM, Krushkal J, Li MC, Chen L, Kotliarov Y, Palmisano A, Pauly R, Xie Q, Williams PM, McShane LM, Zhao Y.
    J Transl Med; 2024 Aug 05; 22(1):733. PubMed ID: 39103840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.
    Oncotarget; 2015 Sep 22; 6(28):26230-41. PubMed ID: 26213847
    [Abstract] [Full Text] [Related]

  • 9. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 10. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis.
    Li G, She FF, Liao CY, Wang ZW, Wang YT, Wu YD, Huang XX, Xie CK, Lin HY, Zhu SC, Chen YH, Wu ZH, Chen JZ, Chen S, Chen YL.
    Cell Death Dis; 2024 Oct 11; 15(10):742. PubMed ID: 39394197
    [Abstract] [Full Text] [Related]

  • 11. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 12. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
    Basu R, Kulkarni P, Swegan D, Duran-Ortiz S, Ahmad A, Caggiano LJ, Davis E, Walsh C, Brenya E, Koshal A, Brody R, Sandbhor U, Neggers SJCMM, Kopchick JJ.
    Int J Mol Sci; 2024 Jul 06; 25(13):. PubMed ID: 39000545
    [Abstract] [Full Text] [Related]

  • 13. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 06; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 14. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S, Wang L, Che D, Zhang M, Li M, Naito M, Xin W, Zhou L.
    J Exp Clin Cancer Res; 2022 Mar 08; 41(1):88. PubMed ID: 35260193
    [Abstract] [Full Text] [Related]

  • 15. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G, Ghosh A, Gupta V, Haque I, Sarkar S, Das A, Dhar K, Bhavanasi S, Gunewardena SS, Von Hoff DD, Mallik S, Kambhampati S, Banerjee SK, Banerjee S.
    Mol Cancer Ther; 2019 Apr 08; 18(4):788-800. PubMed ID: 30787177
    [Abstract] [Full Text] [Related]

  • 16. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
    Shi YH, Xu QC, Zhu YQ, Liu ZD, Zhao GY, Liu Q, Wang XY, Wang JQ, Xu X, Su Q, Lai JM, Huang CS, Yin XY.
    Mol Ther; 2023 Feb 01; 31(2):503-516. PubMed ID: 36384875
    [Abstract] [Full Text] [Related]

  • 17. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL, Fehling SC, Vance RB, Chen D, Brown EJ, Hossain MI, Heard EO, Andrabi SA, Wang H, Yang ES, Buchsbaum DJ, van Waardenburg RCAM, Bellis SL, Yoon KJ.
    Cancer Lett; 2024 Jun 28; 592():216919. PubMed ID: 38704133
    [Abstract] [Full Text] [Related]

  • 18. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L, Hamm J, Stroebel P, Jovan T, Goetze R, Singh S, Hessmann E, Ellenrieder V, Ammer-Herrmenau C, Neesse A.
    Neoplasia; 2024 Jul 28; 53():101002. PubMed ID: 38744194
    [Abstract] [Full Text] [Related]

  • 19. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
    Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N, Yu J, Lee S, Kim J, Qin B, Xie F, Evans D, Wang L, Lou W, Lou Z.
    Cancer Res; 2016 Feb 01; 76(3):572-81. PubMed ID: 26676747
    [Abstract] [Full Text] [Related]

  • 20. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, Huang G, Wang P, Cui C, Fan Y.
    Drug Resist Updat; 2024 May 01; 74():101079. PubMed ID: 38518727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.